Background While going through the literatures, I came across two landmark articles on the evolution of Monoclonal Gammopathy of Unknown Significance (MGUS) and Smoldering Multiple Myeloma (SMM) by the Mayo Clinic Group headed by Dr Robert Kyle. These articles described the evolution of MGUS and SMM into symptomatic myeloma by reporting cumulative proportion of developing symptomatic myeloma in a population based follow up study.
The following figure depicts the progression of MGUS into symptomatic myeloma